Brawn Biotech

{
  "main_header": {
    "sid": 479596,
    "name": "Brawn Biotech",
    "stock_name": "Brawn Biotech",
    "full_name": "Brawn Biotech Ltd",
    "name_url": "stocks-analysis/brawn-biotech",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "20.10",
    "chg": 0.95,
    "chgp": "4.96%",
    "dir": 1,
    "prev_price": "19.15",
    "mcapval": "6.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 530207,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 49,
    "indexname": "India SENSEX",
    "isin": "INE899B01015",
    "curr_date": "Mar 20",
    "curr_time": "",
    "bse_nse_vol": "3.3 k",
    "exc_status": "Active",
    "traded_date": "Mar 20, 2026",
    "traded_date_str": "2026 03 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/brawn-biotech-479596-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Brawn Biotech Ltd Downgraded to Strong Sell Amid Technical and Fundamental Concerns",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/brawn-biotech-ltd-downgraded-to-strong-sell-amid-technical-and-fundamental-concerns-3895734",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/BrawnBiotechLtd_mojoScore_3895734.png",
        "date": "2026-03-17 08:03:20",
        "description": "Brawn Biotech Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 16 Mar 2026, reflecting a deterioration in its technical outlook and persistent fundamental challenges. Despite some positive quarterly financial results, the company’s long-term growth trajectory and valuation metrics remain concerning, prompting a reassessment of its investment appeal within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Brawn Biotech Ltd Downgraded to Strong Sell Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/brawn-biotech-ltd-downgraded-to-strong-sell-amid-mixed-financial-and-technical-signals-3843556",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/BrawnBiotechLtd_mojoScore_3843556.png",
        "date": "2026-02-17 08:05:12",
        "description": "Brawn Biotech Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 16 Feb 2026, reflecting a complex interplay of financial improvements and persistent fundamental weaknesses. Despite positive quarterly financial trends, the company’s valuation, long-term growth prospects, and technical indicators paint a cautious picture for investors navigating the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Brawn Biotech Ltd Rating Upgraded to Sell Amid Mixed Technical and Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/brawn-biotech-ltd-rating-upgraded-to-sell-amid-mixed-technical-and-financial-signals-3834249",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/BrawnBiotechLtd_mojoScore_3834249.png",
        "date": "2026-02-12 08:03:17",
        "description": "Brawn Biotech Ltd’s investment rating has been upgraded from Strong Sell to Sell, reflecting a modest improvement in its technical outlook despite persistent fundamental challenges. The company’s overall Mojo Score now stands at 33.0, signalling cautious investor sentiment amid weak financial trends and valuation concerns. This article analyses the four key parameters—Quality, Valuation, Financial Trend, and Technicals—that influenced this rating revision."
      },
      {
        "title": "Brawn Biotech Ltd Downgraded to Strong Sell Amid Weak Fundamentals and Technical Setbacks",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/brawn-biotech-ltd-downgraded-to-strong-sell-amid-weak-fundamentals-and-technical-setbacks-3827910",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/BrawnBiotechLtd_mojoScore_3827910.png",
        "date": "2026-02-09 08:02:11",
        "description": "Brawn Biotech Ltd has been downgraded from a Sell to a Strong Sell rating by MarketsMOJO as of 6 February 2026, reflecting deteriorating technical indicators and persistently weak financial fundamentals. The company’s Mojo Score has slipped to 23.0, signalling heightened risk for investors amid sideways technical trends and disappointing long-term performance metrics."
      },
      {
        "title": "Brawn Biotech Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/brawn-biotech-ltd-is-rated-sell-3771488",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BrawnBiotechLtd_mojoScore_3771488.png",
        "date": "2025-12-26 21:51:48",
        "description": "Brawn Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 Dec 2025. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 26 December 2025, providing investors with an up-to-date perspective on the company’s performance and outlook."
      }
    ],
    "total": 417,
    "sid": "479596",
    "stock_news_url": "https://www.marketsmojo.com/news/brawn-biotech-479596"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "05-Mar-2026",
      "details": "Newspaper Advertisement for special window for transfer of physical shares.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "16-Feb-2026",
      "details": "Newspaper publication of Unaudited Financial Results for Quarter and year to date ended 31.12.2025.",
      "source": "BSE"
    },
    {
      "caption": "Results - Financial Results For 31/12/2025",
      "datetime": "14-Feb-2026",
      "details": "Unaudited Financial Results for quarter and nine months ended 31.12.2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Brawn Biotech Ltd has declared <strong>10%</strong> dividend, ex-date: 12 Sep 18",
          "dt": "2018-09-12",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Brawn Biotech Ltd Downgraded to Strong Sell Amid Technical and Fundamental Concerns

2026-03-17 08:03:20

Brawn Biotech Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 16 Mar 2026, reflecting a deterioration in its technical outlook and persistent fundamental challenges. Despite some positive quarterly financial results, the company’s long-term growth trajectory and valuation metrics remain concerning, prompting a reassessment of its investment appeal within the Pharmaceuticals & Biotechnology sector.

Read full news article

Brawn Biotech Ltd Downgraded to Strong Sell Amid Mixed Financial and Technical Signals

2026-02-17 08:05:12

Brawn Biotech Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 16 Feb 2026, reflecting a complex interplay of financial improvements and persistent fundamental weaknesses. Despite positive quarterly financial trends, the company’s valuation, long-term growth prospects, and technical indicators paint a cautious picture for investors navigating the Pharmaceuticals & Biotechnology sector.

Read full news article

Brawn Biotech Ltd Rating Upgraded to Sell Amid Mixed Technical and Financial Signals

2026-02-12 08:03:17

Brawn Biotech Ltd’s investment rating has been upgraded from Strong Sell to Sell, reflecting a modest improvement in its technical outlook despite persistent fundamental challenges. The company’s overall Mojo Score now stands at 33.0, signalling cautious investor sentiment amid weak financial trends and valuation concerns. This article analyses the four key parameters—Quality, Valuation, Financial Trend, and Technicals—that influenced this rating revision.

Read full news article

Brawn Biotech Ltd Downgraded to Strong Sell Amid Weak Fundamentals and Technical Setbacks

2026-02-09 08:02:11

Brawn Biotech Ltd has been downgraded from a Sell to a Strong Sell rating by MarketsMOJO as of 6 February 2026, reflecting deteriorating technical indicators and persistently weak financial fundamentals. The company’s Mojo Score has slipped to 23.0, signalling heightened risk for investors amid sideways technical trends and disappointing long-term performance metrics.

Read full news article

Brawn Biotech Ltd is Rated Sell

2025-12-26 21:51:48

Brawn Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 Dec 2025. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 26 December 2025, providing investors with an up-to-date perspective on the company’s performance and outlook.

Read full news article

View All News